Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal
Authors:
- Mohamad NavabMohamad Navab
- G M AnantharamaiahGAG M Anantharamaiah
- Srinivasa T ReddySRSrinivasa T Reddy
- Brian J Van LentenBLBrian J Van Lenten
- Geeta DattaGDGeeta Datta
- David GarberDGDavid Garber
- Alan M FogelmanAFAlan M Fogelman
- 1 December 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 15 (6) , 645-649
Abstract
Recent publications related to the potential use of apolipoprotein (apo)A-I and apoA-I mimetic peptides in the treatment of atherosclerosis are reviewed. A preliminary report indicating that infusion of apoA-IMilano into humans once weekly for 5 weeks caused a significant decrease in coronary artery atheroma volume has sparked great interest in the potential therapeutic use of apoA-I. Recent studies have revealed that HDL quality (e.g. HDL apolipoprotein and lipid content, including oxidized lipids, particle size and electrophoretic mobility, associated enzymatic activities, inflammatory/anti-inflammatory properties, and ability to promote cholesterol efflux) may be more important than HDL-cholesterol levels. Therefore, when developing new strategies to raise HDL-cholesterol concentrations by interfering with HDL metabolism, one must consider the quality of the resulting HDL. In animal models, raising HDL-cholesterol levels by administering oral phospholipids improved both the quantity and quality of HDL and was associated with lesion regression. An apoA-I mimetic peptide, namely 4F synthesized from D-amino acids (D-4F), administered orally to mice did not raise HDL-cholesterol concentrations but promoted the formation of pre-β HDL containing increased paraoxonase activity, resulting in significant improvements in HDL's anti-inflammatory properties and ability to promote cholesterol efflux from macrophages in vitro. Oral D-4F also promoted reverse cholesterol efflux from macrophages in vivo. The quality of HDL may be more important than HDL-cholesterol levels. ApoA-I and apoA-I mimetic peptides appear to have significant therapeutic potential in atherosclerosis.Keywords
This publication has 37 references indexed in Scilit:
- Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDLJournal of Lipid Research, 2004
- Phosphorylation and Stabilization of ATP Binding Cassette Transporter A1 by Synthetic Amphiphilic Helical PeptidesJournal of Biological Chemistry, 2004
- Inflammatory/Antiinflammatory Properties of High-Density Lipoprotein Distinguish Patients From Control Subjects Better Than High-Density Lipoprotein Cholesterol Levels and Are Favorably Affected by Simvastatin TreatmentCirculation, 2003
- Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary SyndromesJAMA, 2003
- High-Density Lipoproteins as an Emerging Therapeutic Target for AtherosclerosisJAMA, 2003
- Apolipoprotein A-I Deficiency Results in Markedly Increased Atherosclerosis in Mice Lacking the LDL ReceptorArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Induction of Fatal Inflammation in LDL Receptor and ApoA-I Double-Knockout Mice Fed Dietary Fat and CholesterolThe American Journal of Pathology, 2003
- Phosphorylation of a Pest Sequence in ABCA1 Promotes Calpain Degradation and Is Reversed by ApoA-IJournal of Biological Chemistry, 2003
- Overexpression of Apolipoprotein A-I Promotes Reverse Transport of Cholesterol From Macrophages to Feces In VivoCirculation, 2003
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977